Related references
Note: Only part of the references are listed.Targeting Huntingtin Expression in Patients with Huntington's Disease
Sarah J. Tabrizi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc3-Conjugated Antisense Oligonucleotides
Yanfeng Wang et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
Analysis of Antisense Oligonucleotides and Their Metabolites with the Use of Ion Pair Reversed-Phase Liquid Chromatography Coupled with Mass Spectrometry
Anna Kaczmarkiewicz et al.
CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY (2019)
Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
Stanley T. Crooke et al.
NUCLEIC ACID THERAPEUTICS (2019)
Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2′-MOE-ASOs
Colby S. Shemesh et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides
Elizabeth J. Ackermann et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2016)
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
Richard S. Finkel et al.
LANCET (2016)
Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
Claudia A. Chiriboga et al.
NEUROLOGY (2016)
Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys
Rosie Z. Yu et al.
NUCLEIC ACID THERAPEUTICS (2016)
Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys
Colby S. Shemesh et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2016)
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Richard S. Geary et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
Asialoglycoprotein receptor mediated hepatocyte targeting - Strategies and applications
Anisha A. D'Souza et al.
JOURNAL OF CONTROLLED RELEASE (2015)
LC-MS of oligonucleotides: applications in biomedical research
Babak Basiri et al.
BIOANALYSIS (2014)
Clinical pharmacokinetics of second generation antisense oligonucleotides
Rosie Z. Yu et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Bioanalytical LC-MS of therapeutic oligonucleotides
William D. van Dongen et al.
BIOANALYSIS (2011)
In Vitro Metabolic Stabilities and Metabolism of 2′-O-(Methoxyethyl) Partially Modified Phosphorothioate Antisense Oligonucleotides in Preincubated Rat or Human Whole Liver Homogenates
Min-Son Baek et al.
OLIGONUCLEOTIDES (2010)
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100
Rosie Z. Yu et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100
Rosie Z. Yu et al.
DRUG METABOLISM AND DISPOSITION (2007)
Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302)
Tanya A. Watanabe et al.
OLIGONUCLEOTIDES (2006)
Share Paper
